ECSP17038100A - Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas - Google Patents

Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Info

Publication number
ECSP17038100A
ECSP17038100A ECIEPI201738100A ECPI201738100A ECSP17038100A EC SP17038100 A ECSP17038100 A EC SP17038100A EC IEPI201738100 A ECIEPI201738100 A EC IEPI201738100A EC PI201738100 A ECPI201738100 A EC PI201738100A EC SP17038100 A ECSP17038100 A EC SP17038100A
Authority
EC
Ecuador
Prior art keywords
solid state
state forms
fused heteroaromatic
chemical entities
pyrrolidinones
Prior art date
Application number
ECIEPI201738100A
Other languages
English (en)
Inventor
Naoki Yoshikawa
Intellectual Property Gmbh Bayer
O'bryan Colin
Development And Quality E I R L Research
Takada Kenzo
Rongliang Chen
Automotiva S A Nakata
Gedeon Nyrt Richter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17038100(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17038100A publication Critical patent/ECSP17038100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen entidades químicas que son inhibidores de la tirosina quinasa del bazo (SYK), a saber, entidades químicas que comprenden 6-((1R,2S)-2-aminociclohexilamino)-7-fluoro-4-(1-metil-1H-pirazol-4-il)-1H-pirrolo[3,4-c]piridina-3(2H)-ona y determinadas formas de estado sólido de este. También se describen métodos para usar las entidades químicas para tratar trastornos como el cáncer.
ECIEPI201738100A 2014-12-18 2017-06-16 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas ECSP17038100A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
ECSP17038100A true ECSP17038100A (es) 2017-12-01

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201738100A ECSP17038100A (es) 2014-12-18 2017-06-16 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Country Status (29)

Country Link
US (3) US10676473B2 (es)
EP (2) EP3233857B1 (es)
JP (3) JP6778195B2 (es)
KR (1) KR102037502B1 (es)
CN (1) CN107108609B (es)
AU (1) AU2015365580B2 (es)
BR (1) BR112017013149B1 (es)
CA (1) CA2970864C (es)
CL (1) CL2017001561A1 (es)
CO (1) CO2017005910A2 (es)
CR (1) CR20170249A (es)
DK (1) DK3233857T3 (es)
DO (1) DOP2017000130A (es)
EA (1) EA032291B1 (es)
EC (1) ECSP17038100A (es)
ES (1) ES2788454T3 (es)
GE (1) GEP20197050B (es)
HK (1) HK1243406A1 (es)
IL (1) IL252941B (es)
MX (1) MX2017007162A (es)
NZ (1) NZ732371A (es)
PE (1) PE20171179A1 (es)
PH (1) PH12017501123A1 (es)
PL (1) PL3233857T3 (es)
SG (1) SG11201701911QA (es)
TN (1) TN2017000080A1 (es)
UA (1) UA120632C2 (es)
WO (1) WO2016097862A2 (es)
ZA (1) ZA201701800B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233857B1 (en) * 2014-12-18 2020-03-11 Takeda Pharmaceutical Company Limited Solid state forms of fused heteroaromatic pyrrolidinones
US20190231757A1 (en) * 2016-07-13 2019-08-01 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
JP2020537678A (ja) 2017-10-19 2020-12-24 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
EP3896063B1 (en) * 2018-12-14 2024-01-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
WO2020161663A1 (en) 2019-02-07 2020-08-13 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
EP4041714B1 (en) 2019-10-10 2023-12-13 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
EP4337216A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
WO2022237719A1 (en) 2021-05-11 2022-11-17 Janssen Pharmaceutica Nv Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
GEP20156243B (en) * 2009-12-23 2015-02-10 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
EP3233857B1 (en) * 2014-12-18 2020-03-11 Takeda Pharmaceutical Company Limited Solid state forms of fused heteroaromatic pyrrolidinones

Also Published As

Publication number Publication date
EP3233857B1 (en) 2020-03-11
GEP20197050B (en) 2019-12-10
JP6778195B2 (ja) 2020-10-28
US20160176869A1 (en) 2016-06-23
UA120632C2 (uk) 2020-01-10
DOP2017000130A (es) 2017-07-15
EP3677582B1 (en) 2023-01-25
US20200339573A1 (en) 2020-10-29
CR20170249A (es) 2017-09-25
ES2788454T3 (es) 2020-10-21
IL252941B (en) 2020-11-30
HK1243406A1 (zh) 2018-07-13
JP6974534B2 (ja) 2021-12-01
CL2017001561A1 (es) 2018-01-12
BR112017013149B1 (pt) 2022-10-11
EP3233857A2 (en) 2017-10-25
JP2017537969A (ja) 2017-12-21
WO2016097862A3 (en) 2016-08-11
EA201791369A1 (ru) 2017-10-31
ZA201701800B (en) 2020-05-27
PL3233857T3 (pl) 2020-07-27
KR102037502B1 (ko) 2019-10-28
JP2020143081A (ja) 2020-09-10
EA032291B1 (ru) 2019-05-31
US10676473B2 (en) 2020-06-09
EP3677582A1 (en) 2020-07-08
US11352355B2 (en) 2022-06-07
CN107108609A (zh) 2017-08-29
KR20170095374A (ko) 2017-08-22
SG11201701911QA (en) 2017-04-27
NZ732371A (en) 2023-04-28
IL252941A0 (en) 2017-08-31
PH12017501123A1 (en) 2017-11-27
JP2022017477A (ja) 2022-01-25
BR112017013149A2 (pt) 2018-04-10
US20230348461A1 (en) 2023-11-02
CN107108609B (zh) 2020-02-18
CA2970864C (en) 2020-04-14
TN2017000080A1 (en) 2018-07-04
WO2016097862A2 (en) 2016-06-23
CO2017005910A2 (es) 2017-10-20
AU2015365580A1 (en) 2017-07-06
DK3233857T3 (da) 2020-04-27
AU2015365580B2 (en) 2020-04-02
MX2017007162A (es) 2017-08-28
PE20171179A1 (es) 2017-08-22
CA2970864A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
ECSP17038100A (es) Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20180521A1 (es) Inhibidores de tirosina-cinasas
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
SI3419978T1 (sl) Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK)
EA201791133A1 (ru) Ингибиторы erk
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
AR101905A1 (es) Compuestos bicíclicos
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
SI3227297T1 (sl) 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
SI3362453T1 (sl) Derivati cikličnega etra pirazolo(1,5-A)pirimidin-3-karboksiamida
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
CL2016003102A1 (es) 1h-1,8-naftiridin-2-onas como compuestos antiproliferativos.
MX2017017119A (es) Formulacion de alta concentracion.
ECSP18000097A (es) Inhibidores de tirosina-cinasas
UA96860U (xx) Похідні [1,2,4]триазоло[4,3-а]піразину